Lobe Sciences Ltd
Lobe Sciences Ltd., a biopharmaceutical company, engages in the research and development of lipid technology to develop innovative treatments for orphan and rare diseases. It offers Altemia® MF, a medical food designed to manage deficiencies in sickle cel disease. Lobe Sciences Ltd. was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. The … Read more
Lobe Sciences Ltd (LOBEF) - Total Liabilities
Latest total liabilities as of November 2025: $3.33 Million USD
Based on the latest financial reports, Lobe Sciences Ltd (LOBEF) has total liabilities worth $3.33 Million USD as of November 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Lobe Sciences Ltd - Total Liabilities Trend (2017–2025)
This chart illustrates how Lobe Sciences Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Lobe Sciences Ltd Competitors by Total Liabilities
The table below lists competitors of Lobe Sciences Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ecofibre Limited
PINK:EOFBF
|
USA | $32.89 Million |
|
Aviv Arlon Ltd
TA:AVLN
|
Israel | ILA407.00K |
|
TUGA Innovations Inc
PINK:TUGAF
|
USA | $1.82 Million |
|
RHEPA
PINK:RHEPA
|
USA | $69.00 Million |
|
LN Future Invest AB (publ)
ST:LNFI
|
Sweden | Skr4.67 Million |
|
FRESNILLO
BE:FNL
|
Germany | €1.67 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Lobe Sciences Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lobe Sciences Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lobe Sciences Ltd (2017–2025)
The table below shows the annual total liabilities of Lobe Sciences Ltd from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-08-31 | $2.70 Million | -19.98% |
| 2024-08-31 | $3.37 Million | +37.13% |
| 2023-08-31 | $2.46 Million | +88.91% |
| 2022-08-31 | $1.30 Million | +61.80% |
| 2021-08-31 | $804.70K | -10.30% |
| 2020-08-31 | $897.09K | +70.04% |
| 2019-08-31 | $527.56K | +299.42% |
| 2018-08-31 | $132.08K | +1896.40% |
| 2017-08-31 | $6.62K | -- |